Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2011

Jun 2, 2011

151_ip_2011-06-02_223f6900-edd7-407d-9854-44046d7e52e3.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Building innovative drug discovery alliances

Go o G O f r GROWTH! Acquisition of Compou und Focus Inc.

Evotec AG, Investor and Analyst call, 1st June 2011

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this report. Such forward-lo are neither promises nor guarantees, bu variety of risks and uncertainties, man ntation containsolve a number ofoking statements nt of Evotec as ofooking statements ut are subject to a ny of which are

beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements We e pressl disclaim an forward-lookingstatements. expressly any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Acquisition of Com mpound Focus Inc.

Summary

Strategic rational g

• Evotec expands integrated drug discovery profitable offering in compound manageme alliance solutions with best in class, ent

Structure

E t i ll h i C d F• Evotec acquires all shares in Compoundcompany; If ocus Inc. from Bi Foocus, a G lá a pagos

Total deal value €12.5m in cash

Upfront: €10 25m; earn 10.25m; earn-out of up to out €2 25m . on revenues and certain corporate milesto m payable over the next 2 years depending m, years, nes

  • • Compound Focus, Inc. will be renamed into within the Evotec group; business will be fu structureso"Evotec (San Francisco) Inc." as US entity ully integrated into Evotec's global operating
  • • Transaction will add ca. €6 – 8m revenues p py .a. with solid profitability

Agenda

• Market opportunity & & strategic rational

  • • Company profile and c competitive advantage
  • • Transaction & Outlook k

Building best in cl infrastructuresass drug y discovery

Strategic imperatives for o our business model

Better solutions fodiscovery alliance or integrated drug es

Strategic rational of acquis sition

Industry drivers in compound manageme ent

High expenses in specialized infrastructure (IT, robotics, analytical support) 1

Complexity of tracking and managing data compound handling 2 data,

Variety of storage conditions, 3yg safeguarding compound integrity

Regulatory reliance, speed and cost efficiency 4

  • • Increasing outsourcing of compound management
  • • Critical for government and NFPO's with no capabilities
  • • Efficiencies improved by modern technology platforms
  • • Few competitors due to high costs ofentry
  • • Compound Focus clear market leader and opportunities for growth through added services and market reach

Compound manag our alliancesgement as an integrated solution in

Role of compound manage ement in Evotec's value chain

Best practice operations

An even better Evootec

Where is the fit?

  • • Unique outsourcing partner fo long-term incentive linked to c management or all research projects with a comp g ound storage and
  • • Government organisations an customers can access other Eversa (cross selling synergies nd existing p Com ound Focus Evotec services and vice s)

Agenda

  • • Market opportunity & s strategic rational
  • • Company profile and d competitive advantage
  • • Transaction & Outlook k

Compound Focus – leader in a niche market

Purchase, Storage and Ma anagement of Compound Libraries

Quality leadership p position fits to Evotec offerings

Market position of Compo ound Focus

Selected players in the marketplace - Potentia al market opportunity ca. € 50m p.a.

  • •In house Pharma
  • •SPECS (Europe)
  • •Sigma Aldrich
  • •ASDI

Strong market presence – Compound Focus has signed 6 of the last 9 si ignificant contracts in compound management

A stable, profitable e business, ready to grow

Historic performance & an nd revenue profile

Agenda

  • • Market opportunity & s strategic rational
  • • Company profile and c competitive advantage
  • • Transaction & Outlo ok

Acquisition of Com mpound Focus Inc.

Terms and integration

E
i
l
l
h
i
C
d
F
I
t
o
e
c
a
c
q
r
e
s
a
s
a
r
e
s
n
o
o
m
p
o
n
o
c
s
n
c
v
u
u
u
•
T
l
D
l
€
1
2
i
h
5
t
o
a
e
a
m
n
c
a
s
•
i
T
t
r
a
n
s
a
c
o
n		 S
C
d
i
d
i
t
t
t
r
u
c
u
r
e
a
n
o
n
s
e
r
a
o
n
:
•
U
f
€
1
0
2
5
t
p
r
o
n
m
:
−
E
f
€
b
l
i
h
i
l
l
h
2
2
5
2
t
t
t
t
t
t
t
a
r
n
-o
o
p
o
m
p
a
a
e
n
r
e
e
n
s
a
m
e
n
s
o
e
r
e
n
e
e
a
r
s
u
u
y
y
v
x
y
−
,
,
d
d
i
h
f
d
i
i
l
t
t
t
t
t
e
p
e
n
n
g
o
n
r
e
a
c
o
r
e
e
n
e
a
r
g
e
s
a
n
c
e
r
a
n
c
o
r
p
o
r
a
e
m
e
s
o
n
e
s
v
u
u
S
h
d
l
l
i
i
f
i
k
f
J
t
a
r
e
e
a
c
o
s
n
g
n
r
s
e
e
e
o
n
e
w
u
−
I
i
t
t
n
e
g
g
r
a
o
n		 C
"E
(
S
)
d
F
I
i
l
l
b
d
F
i
I
"
t
o
m
p
o
u
n
o
c
u
s
n
c
w
e
r
e
n
a
m
e
v
o
e
c
a
n
r
a
n
c
s
c
o
n
c
•
,
C
d
F
i
l
l
b
i
d
i
E
'
D
D
i
O
i
t
t
t
t
t
o
m
p
o
n
o
c
s
e
n
e
g
r
r
a
e
n
o
o
e
c
s
r
g
s
c
o
e
r
p
e
r
a
o
n
s
u
u
w
v
u
v
y
•
---------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Global reach for g lobal projects

Ca. 580 Evotec employees s worldwide

Compound Focus 2011adds approx. €3 - 4 m revenues in

Deal will be fully accretive e in 2011

in € m

F
Y
G
i
d
u
a
n
c
e
/
3
2
0
1
1		 N
F
Y
e
w
G
G
i
i
d
d
u
a
n
c
e		 6
4
6
6		 6
8
0
7
-
R
e
e
n
e
s
v
u		 6
4
6
6
-		 6
8
0
7
–		 - 4
O
i
i
t
p
e
r
a
n
g
n
c
o
m
e
(
l
)
o
s
s		 I
d
m
p
r
o
e
v
2
0
1
0
o
e
r
v		 I
d
m
p
r
o
e
v
2
0
1
0
o
e
r
v
N
i
t
e
n
c
o
m
e
(
)
l
o
s
s		 I
d
m
p
r
o
v
e
2
0
1
0
o
v
e
r		 I
d
m
p
r
o
v
e
2
0
1
0
o
v
e
r
U
d
t
n
p
a
r
n
e
r
e
R
&
D
e
p
e
n
s
e
s
x		 1
0
a
p
p
r
o
x		 1
0
0
a
p
p
r
o
x
L
i
i
d
i
t
t
q
u
y
a
i
d
d
p
e
r
o
e
n		 )
1
6
5		 )
1
5
5		 O
r
g
a
n
B
i
s
n
e
u		 i
c
s
s		 C
d
o
m
p
o
n
u
F
o
c
s
u		 g N
e
w
i
d
a
n
c
e
u

Strong news flow to come

Outlook and next steps for r 2011 ff

Key milestones for 2011

d
i
G
r
o
s
c
o
e
r
w
v
y		 •
l
l
i
b
i
l
d
a
a
n
c
e
s
u
,		 •
1
j
j
i
i
i
t
t
o
n
n
n
o
v
a
o
n		 •
l
l
i
a
a
n
c
e
s
  • • Build at least two signific cant new integrated technology/disease alliances
  • • Deliver significant and a accelerated preclinical/clinical milestones
  • • Show expansion succes ssof existing alliances alliances
  • • Show operational synerg gies of acquisitions

Generateoptimal pipeline progress & biotech values2

  • • At least 1 strategic deal for an early asset
  • • Generate more innovatioon upsides (e.g. Harvard cooperation, …)

Manage •and path to profitability 3

  • Prepare growth of reven innovationnues by more than 15% y-o-y into 2012ff
  • • Build profitability, withou ut infringing innovation power
  • • Keep strong strategic ca ash position

Building innovative drug discovery alliances

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.() 6 8 0 .40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
AGM Information 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →